Which advantages over its rivals hold up, and why are they hard to copy?
At Sai Life Sciences, manufacturing sites undergo both customer audits and regulatory inspections, meaning quality assertions receive outside verification rather than remaining self-reported. By March 2025 the units had passed over 75 customer audits during the previous three years, and they hold approvals from the USFDA, PMDA (Japan), and CDSCO (India).
Sai Life Sciences works with more than 300 global innovator pharmaceutical and biotech firms. Its Bidar site holds roughly 700 KL of total installed reactor capacity.
2Product Overview
What does the product do for its buyer, and how is it delivered?
Sai Life Sciences is a contract research, development and manufacturing organization (CRDMO) that sells contract development and manufacturing services to innovator drug companies. It runs a flagship API plant at Bidar, India, where the site produces APIs and advanced intermediates for the US, EU, and Japan, and its discovery services span medicinal and synthetic chemistry, biology, DMPK, and toxicology.
The Bidar facility has about 700 KL of total installed reactor capacity and has been inspected and approved by the USFDA, PMDA (Japan), and CDSCO (India).
